ORPN Bio Blast Pharma Ltd. gains 26% May 18, 2018

Bioblast Pharma Ltd., a clinical-stage biotechnology company, focuses on the development of clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. It develops Trehalose 90mg/mL IV solution, a protein stabilizer and autophagy enhancer to treat patients with oculopharyngeal muscular dystrophy and spinocerebellar ataxia type 3. The company was founded in 2012 and is headquartered in Tel Aviv, Israel.http://www.priceseries.com/trade/ORPN-Bio-Blast-Pharma-Ltd-stock-gains-26-percent-a-Trade-Record-by-priceSeries-2018051620180518.html